Deferoxamine-related ocular toxicity: Incidence and outcome in a pediatric population

Retina

Volumn 28, Issue 6, 2008, Pages 894-899

  Baath, Jasrajbir S ^a   Lam, Wai Ching ^b   Kirby, Melanie ^b   Chun, Anne ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

Deferoxamine; Retinopathy; Toxicity

Indexed keywords

DEFEROXAMINE; VISUAL PIGMENT; IRON CHELATING AGENT; SIDEROPHORE;

ADOLESCENT; ARTICLE; BLURRED VISION; BONE DYSPLASIA; CANADA; CHILD; CONTINUOUS INFUSION; DRUG MEGADOSE; ELECTRORETINOGRAPHY; EYE EXAMINATION; EYE TOXICITY; FEMALE; HEMOCHROMATOSIS; HUMAN; HYPOACUSIS; INCIDENCE; INFANT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; OUTCOME ASSESSMENT; PEDIATRIC HOSPITAL; PRESCHOOL CHILD; RETINA PIGMENT DEGENERATION; RETROSPECTIVE STUDY; SCHOOL CHILD; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; MONITORING; RETINA; RETINA DISEASE; VISUAL ACUITY; VISUAL DISORDER; VISUAL FIELD;

CHILD; DEFEROXAMINE; FEMALE; HEMOCHROMATOSIS; HUMANS; INCIDENCE; IRON CHELATING AGENTS; MALE; MONITORING, PHYSIOLOGIC; RETINA; RETINAL DISEASES; RETROSPECTIVE STUDIES; SIDEROPHORES; VISION DISORDERS; VISUAL ACUITY; VISUAL FIELDS;

EID: 47749103386     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181679f67     Document Type: Article

References (20)

1. Chan YL, Chu CW, Chik KW, et al. Deferoxamine-induced dysplasia of the knee: sonographic features and diagnostic performance compared with magnetic resonance imaging. J Ultrasound Med 2001;20:723-728.
2. Chen SH, Liang DC, Lin HC, et al. Auditory and visual toxicity during deferoxamine therapy in transfusion-dependent patients. J Pediatr Hematol Oncol 2005;27:651-653.
3. Davies SC, Marcus RE, Hungerford JL, et al. Ocular toxicity of high-dose intravenous desferrioxamine. Lancet 1983;2: 181-184.
4. Marciani MG, Cianciulli P, Stefani N, et al. Toxic effects of high-dose deferoxamine treatment in patients with iron overload: an electrophysiological study of cerebral and visual function. Haematologica 1991;76:131-134.
5. Lakhanpal V, Schocket SS, Jiji R. Deferoxamine (Desferal) induced toxic retinal pigment degeneration and presumed optic neuropathy. Ophthalmology 1984;91:443-451.
6. Orton RB, de Veber LL, Sulh HM. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy. Can J Ophthalmol 1985;20:153-156.
7. Blake DR, Winyard P, Lunec J, et al. Cerebral and ocular toxicity induced by desferrioxamine. Q J Med 1985;56:344- 355.
8. Bournerias F, Monnier N, Dufier JL, Reveillaud RJ. Severe ocular toxicity of desferrioxamine in the hemodialyzed patient. Nephrologie 1987;8:27-29.
9. Kaplinsky C, Stark B, Goshen Y. Deferoxamine (Desferal)-induced ocular toxicity. Pediatr Hematol Oncol 1988;5:293- 297.
10. Bene C, Manzler A, Bene D, Kranias G. Irreversible ocular toxicity from a single "challenge" dose of deferoxamine. Clin Nephrol 1989;31:45-48.
11. Ravelli M, Scaroni P, Mombelloni S, et al. Acute visual disorders in patients on regular dialysis given desferrioxamine as a test. Nephrol Dial Transplant 1990;5:945- 949.
12. Cases A, Kelly J, Sabater F, et al. Ocular and auditory toxicity in hemodialyzed patients receiving desferrioxamine. Nephron 1990;56:19-23.
13. Dennerlain JA, Lang GE, Stahnke K, et al. Ocular findings in Desferal therapy. Ophthalmologe 1995;92:38-42.
14. Rahi AH, Hungerford JL, Ahmed AI. Ocular toxicity of desferrioxamine: light microscopic histochemical and ultrastructural findings. Br J Ophthalmol 1986;70:373-381.
15. De Virgiliis S, Congia M, Turco MP, et al. Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassemia. Arch Dis Child 1988;63:250-255.
16. Pall H, Blake DR, Winyard P, et al. Ocular toxicity of desferrioxamine: an example of copper promoted auto-oxidative damage? Br J Ophthalmol 1989;73:42-47.
17. Haimovici R, D'Amico DJ, Gragoudas ES, Sokol S. The expanded clinical spectrum of deferoxamine retinopathy. Ophthalmology 2002;109:164-171.
18. Wilson JMG, Junger G. Principles and Practice of Screening for Disease. [Spanish] Bol Oficina Sanit Panam 1968;65:281-393.
19. Hidajat RR, Mclay JL, Goode DH, Spearing RL. EOG as a monitor of desferrioxamine retinal toxicity. Doc Ophthalmol 2004;109:273-278.
20. Kertes PJ, Lee TK, Coupland SG. The utility of multifocal electroretinography in monitoring drug toxicity: deferoxamine retinopathy. Can J Ophthalmol 2004;39:656-661.